Your browser is no longer supported. Please, upgrade your browser.
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.82 Insider Own0.20% Shs Outstand22.76M Perf Week-5.58%
Market Cap388.97M Forward P/E- EPS next Y-1.93 Insider Trans- Shs Float19.97M Perf Month21.46%
Income-39.30M PEG- EPS next Q-0.37 Inst Own81.90% Short Float7.46% Perf Quarter-0.75%
Sales- P/S- EPS this Y-98.80% Inst Trans14.50% Short Ratio3.91 Perf Half Y-16.84%
Book/sh5.48 P/B3.12 EPS next Y5.40% ROA-66.60% Target Price30.33 Perf Year-
Cash/sh5.36 P/C3.19 EPS next 5Y- ROE81.30% 52W Range11.81 - 26.75 Perf YTD-7.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.11% Beta-
Dividend %- Quick Ratio11.00 Sales past 5Y- Gross Margin- 52W Low44.71% ATR0.95
Employees25 Current Ratio11.00 Sales Q/Q- Oper. Margin- RSI (14)58.61 Volatility4.37% 6.61%
OptionableYes Debt/Eq0.20 EPS Q/Q-35.90% Profit Margin- Rel Volume0.28 Prev Close16.93
ShortableYes LT Debt/Eq0.14 EarningsFeb 27 Payout- Avg Volume380.97K Price17.09
Recom1.30 SMA206.70% SMA5013.20% SMA200-7.73% Volume105,333 Change0.95%
Mar-19-18 08:00AM  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call Business Wire
Mar-14-18 08:00AM  Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference Business Wire
Mar-05-18 08:00AM  Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair Business Wire
Jan-26-18 04:48PM  Largest Insider Trades of the Week
Jan-25-18 08:10AM  New Research: Key Drivers of Growth for Comstock Resources, Varonis, Union Bankshares, Heidrick & Struggles International, Tejon Ranch, and Kala Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-05-18 04:32PM  Here's Why Kala Pharmaceuticals Got Crushed on Friday Motley Fool -29.28%
10:13AM  Kala shares decline 8% on late-stage trial results for dry eye therapy MarketWatch
09:46AM  Future of Kala Pharma's dry eye drug uncertain after mixed results Reuters
07:00AM  Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease Business Wire
06:50AM  Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration Business Wire
Nov-13-17 08:00AM  Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer Business Wire
Nov-07-17 07:30AM  Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update Business Wire
Oct-30-17 09:34AM  [$$] Private Equity Analyst's 2017 Women to Watch: Venture Capital The Wall Street Journal
Oct-25-17 08:00AM  Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%) Business Wire
Sep-05-17 08:00AM  Kala Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference Business Wire
Aug-14-17 01:57PM  Kala Pharma Has 2 Material Milestones Upcoming In Q4 Benzinga +9.31%
Jul-25-17 04:05PM  Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters Option Business Wire
Jul-23-17 10:36AM  IPOs This Week: Real Estate Unicorn Redfin Leads Weeks IPOs 24/7 Wall St.
Jul-20-17 11:36AM  Kala Pharmaceuticals Joins NASDAQ, the Biotech IPOs Keep Coming
10:49AM  [$$] Kala Pharmaceuticals Prices IPO at Midpoint of Range The Wall Street Journal
08:06AM  Kala Pharmaceuticals prices IPO at $15 a share MarketWatch
08:00AM  Kala Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen HongmingChief Scientific OfficerFeb 28Option Exercise2.269,76922,12355,849Mar 02 05:19 PM
ORBIMED ADVISORS LLC10% OwnerFeb 08Buy12.9325,000323,2503,447,840Feb 12 04:35 PM
ORBIMED ADVISORS LLC10% OwnerFeb 02Buy14.7337,840557,3833,422,840Feb 06 05:05 PM
ORBIMED ADVISORS LLC10% OwnerFeb 01Buy14.9922,840342,3723,385,000Feb 02 05:45 PM
ORBIMED ADVISORS LLC10% OwnerJan 31Buy15.00339,4005,091,0003,362,160Feb 02 05:45 PM
ORBIMED ADVISORS LLC10% OwnerJan 29Buy14.9950,000749,5003,022,760Jan 30 03:34 PM
ORBIMED ADVISORS LLC10% OwnerJan 26Buy14.9322,760339,8072,972,760Jan 30 03:34 PM
ORBIMED ADVISORS LLC10% OwnerJan 24Buy14.9164,637963,7382,950,000Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 23Buy14.994,36365,4012,885,363Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 22Buy14.9875,0001,123,5002,881,000Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 19Buy14.9574,9311,120,2182,806,000Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 12Buy14.5038,354556,1332,731,069Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 12Buy15.4028,446438,0682,692,715Jan 12 05:29 PM
ORBIMED ADVISORS LLC10% OwnerJan 11Buy13.6541,700569,2052,664,269Jan 12 05:29 PM
ORBIMED ADVISORS LLC10% OwnerJan 10Buy12.83170,3382,185,4372,622,569Jan 12 05:29 PM